New Mentalin Sustained Release Capsule 16 mg (Galantamine Bromide)

Adult dose

Administer once daily in the morning. Administration immediately after breakfast is preferable. Swallow this medicine whole with an adequate amount of water; do not chew or crush it. Ensure adequate fluid intake while taking this medicine. Initial dose: 8 mg once daily is recommended for the first 4 weeks. Maintenance dose: - After the initial dose, administer 16 mg once daily for at least 4 weeks. - Thereafter, the dose may be increased to a maximum of 24 mg daily based on evaluation of clinical benefit, tolerability, etc. - For patients who do not tolerate 24 mg daily or whose response does not improve, consider reducing the dose to 16 mg daily. - This medicine may be continued as long as the patient benefits from treatment. Regularly assess its clinical benefit, and consider discontinuing treatment if there is no therapeutic effect. - No rebound phenomenon occurs after discontinuation of treatment (e.g., in preparation for surgery). For patients with moderate hepatic impairment, based on pharmacokinetic modeling, administer 8 mg every other day for at least 1 week; morning administration is preferable. Thereafter, administer 8 mg once daily for at least 4 weeks. Do not exceed 16 mg daily. This medicine is contraindicated in patients with severe hepatic impairment (Child-Pugh score >9). No dosage adjustment is necessary in patients with mild hepatic impairment. No dosage adjustment is necessary in patients with creatinine clearance of 9mL/min or greater. This medicine is contraindicated in patients with severe renal impairment (creatinine clearance < 9mL/min). Consider reducing the dose of this medicine in patients receiving CYP 2D6 or CYP 3A4 inhibitors (e.g., ketoconazole).

Child dose

Use in children is not recommended.

This medication should not be used in patients with hypersensitivity to its components, or in patients with severe liver or kidney impairment. Various adverse reactions may occur during administration, such as nausea, vomiting, diarrhea, dizziness, headache, fatigue, and symptoms should be closely monitored. If skin rashes or severe skin reactions occur, discontinue use immediately and consult a medical professional. This medication is intended for patients with mild to moderate Alzheimer's type dementia and has not been proven effective for other types of dementia or memory disorders. Patients with heart disease or bradycardia may experience cardiac-related adverse reactions, so caution is needed during use. Patients with gastrointestinal diseases or a history of ulcers should closely observe symptoms to prevent gastrointestinal symptom exacerbation during usage. Attention is required for patients with asthma, obstructive lung disease, or those recovering from bladder surgery when using this medication. It is advisable not to combine this medication with other cholinergic drugs, and there is a risk of excessively low heart rate if taken with specific heart medications. During pregnancy, the risks to the fetus and the benefits of this medication should be carefully considered, and it is recommended that breastfeeding women refrain from its use. During the first week of treatment, dizziness or drowsiness may occur, so caution is required when driving or operating machinery. In case of overdose, symptoms such as vomiting, bradycardia, and convulsions may appear, and immediate medical attention should be sought, with antidotes used if necessary. Keep this medication out of the reach of children and do not transfer it to other containers to maintain its quality.

Decreased appetite, depression, dizziness, headache, tremors, syncope, somnolence, drowsiness, bradycardia, nausea, vomiting, diarrhea, abdominal pain, upper abdominal pain, dyspepsia, abdominal discomfort, muscle spasms, fatigue, weakness, lethargy, weight loss, falls, lacerations, dehydration, altered taste, hypersomnia, sensory disturbances, blurred vision, I degree atrioventricular block, palpitations, bradycardia, ventricular premature contractions, flushing, hypotension, nausea, sweating, muscle weakness, hypersensitivity, hallucinations, visual hallucinations, auditory hallucinations, seizures, tinnitus, complete atrioventricular block, hypertension, hepatitis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, elevated liver enzymes, rash, itching, extrapyramidal syndrome, Parkinson's syndrome, exacerbation of Parkinson's syndrome, hand paralysis, bradykinesia, Pisa syndrome, delirium, sweating, edema, constipation, dry mouth, gastritis, belching, jaundice, elevated γ-GT, elevated ALT/AST, exacerbation of chronic renal failure, urinary incontinence, vertigo, sweating, gastrointestinal cramping, salivation, tearing, defecation, urination, exhaustion, torsades de pointes, ventricular tachycardia, transient loss of consciousness

This medication should be stored in a tightly sealed container to prevent air ingress, ideally between 1 to 30 degrees Celsius at room temperature. Proper storage will help maintain the medication's effectiveness and prevent deterioration.

Appearance

An opaque pink hard capsule containing white to nearly white sustained release coated pellets.

Package unit

30 capsules/bottle